30 May 2023

BerGenBio ASA: Receipt of subscription rights in the rights issue by primary insiders and their close associates

Bergen 30 May 2023: Reference is made to the stock exchange announcement published by BerGenBio ASA (the “Company”) earlier today, 30 May 2023, regarding the commencement of the subscription period in the rights issue (the “Rights Issue”). As part of this process, subscription rights have been allocated to primary insiders and their close associates.

Martin Olin, CEO of BerGenBio ASA, has on 30 May 2023 acquired 1 046 125 subscription rights in BerGenBio ASA with no price payable.

Anders Tullgren, Chairman of the Board of Directors of BerGenBio ASA, has on 30 May 2023 acquired 1 409 872 subscription rights in BerGenBio ASA with no price payable.

Sveinung Hole, Member of the Board of Directors of BerGenBio ASA, has on 30 May 2023 acquired 83 182 subscription rights in BerGenBio ASA with no price payable.

Svev AS, a company closely associated to Sveinung Hole, Member of the Board of Directors of BerGenBio ASA, has on 30 May 2023 acquired 2 945 053 subscription rights in BerGenBio ASA with no price payable.

Sarsia Seed AS, a company closely associated to Sveinung Hole, Member of the Board of Directors of BerGenBio ASA, has on 30 May 2023 acquired 59 719 358 subscription rights in BerGenBio ASA with no price payable.

Sarsia Development AS, a company closely associated to Sveinung Hole, Member of the Board of Directors of BerGenBio ASA, has on 30 May 2023 acquired 33 131 992 subscription rights in BerGenBio ASA with no price payable.

Please see the attached notifications of trade for information regarding the primary insiders’ and their close associates’ receipt of subscription rights in the Rights Issue.

This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.

Attachments
PDF

PDF

PDF

About Oncoinvent

Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.

This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.

Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.

Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close